HUP0401355A2 - Kombinált immunterápiás készítmények gangliozidokat túlexpresszáló tumorok kezelésére - Google Patents

Kombinált immunterápiás készítmények gangliozidokat túlexpresszáló tumorok kezelésére

Info

Publication number
HUP0401355A2
HUP0401355A2 HU0401355A HUP0401355A HUP0401355A2 HU P0401355 A2 HUP0401355 A2 HU P0401355A2 HU 0401355 A HU0401355 A HU 0401355A HU P0401355 A HUP0401355 A HU P0401355A HU P0401355 A2 HUP0401355 A2 HU P0401355A2
Authority
HU
Hungary
Prior art keywords
idiotypic
antibody
days
units
size
Prior art date
Application number
HU0401355A
Other languages
English (en)
Inventor
Luis Enrique Fernández Molina
Ana María Vázquez López
Rolando Pérez Rodríguez
Alexis Pérez González
Pérez Adriana Carr
Yildian Díaz Rodríguez
Mauro A. Alfonso Fernández
Original Assignee
Centro De Immunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Immunologia Molecular filed Critical Centro De Immunologia Molecular
Publication of HUP0401355A2 publication Critical patent/HUP0401355A2/hu
Publication of HUP0401355A3 publication Critical patent/HUP0401355A3/hu
Publication of HU228106B1 publication Critical patent/HU228106B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A találmány az immunológia szakterületére vonatkozik, közelebbről, atalálmány tárgyát immunterápiás kombinációk képezik tumoroknövekedésének és/vagy sejtproliferációjának befolyásolására. Atalálmány gyakorlati megvalósítása során tumorok elleni terápiás hatásfigyelhető meg azáltal, hogy fő aktív komponensként gangliozid elleniellenanyagot (Ab1) tartalmazó idiotípus-vakcinákat kombinálnak olyanidiotípusvakcinákkal, amelyek fő aktív komponensként anti-gangliozidellenanyag elleni antiidiotípus ellenanyagot (Ab2) tartalmaznak; vagyolyan vakcinákkal, amelyek fő aktív komponensként egy vagy többgangliozidot tartalmaznak. Az ilyen vakcinakombinációk szinergistaterápiás hatást fejtenek ki tumorok ellen. A fenti kombinációkgangliazidokat expresszáló különböző tumorokban szenvedő egyénekkezelésére alkalmazhatók. Ó
HU0401355A 2001-04-06 2002-04-08 Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides HU228106B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2001008420010084A CU23007A1 (es) 2001-04-06 2001-04-06 Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
PCT/CU2002/000002 WO2002081661A2 (es) 2001-04-06 2002-04-08 Combinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos

Publications (3)

Publication Number Publication Date
HUP0401355A2 true HUP0401355A2 (hu) 2004-10-28
HUP0401355A3 HUP0401355A3 (en) 2012-05-29
HU228106B1 HU228106B1 (en) 2012-11-28

Family

ID=40291118

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0401355A HU228106B1 (en) 2001-04-06 2002-04-08 Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides
HU0401695A HU228105B1 (en) 2001-04-06 2002-04-08 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours

Family Applications After (1)

Application Number Title Priority Date Filing Date
HU0401695A HU228105B1 (en) 2001-04-06 2002-04-08 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours

Country Status (37)

Country Link
US (3) US20050069535A1 (hu)
EP (3) EP1384726B1 (hu)
JP (2) JP4366080B2 (hu)
KR (3) KR100863509B1 (hu)
CN (3) CN101054417B (hu)
AR (2) AR033123A1 (hu)
AT (3) ATE477279T1 (hu)
AU (3) AU2002308348B2 (hu)
BG (2) BG66293B1 (hu)
BR (3) BR0208676B1 (hu)
CA (2) CA2443372C (hu)
CU (1) CU23007A1 (hu)
CZ (2) CZ296276B6 (hu)
DE (2) DE60223547T2 (hu)
DK (2) DK1384726T3 (hu)
EA (2) EA006936B1 (hu)
EC (2) ECSP034788A (hu)
ES (2) ES2296986T3 (hu)
HK (3) HK1066818A1 (hu)
HR (2) HRP20030806B1 (hu)
HU (2) HU228106B1 (hu)
IL (2) IL158246A0 (hu)
IS (2) IS6965A (hu)
MX (2) MXPA03008739A (hu)
MY (3) MY145703A (hu)
NO (2) NO20034437L (hu)
NZ (2) NZ528598A (hu)
PE (1) PE20020972A1 (hu)
PL (2) PL208109B1 (hu)
PT (2) PT1384726E (hu)
SG (1) SG161737A1 (hu)
SI (2) SI1411064T1 (hu)
SK (2) SK287783B6 (hu)
UA (3) UA75393C2 (hu)
UY (2) UY27242A1 (hu)
WO (2) WO2002081496A2 (hu)
ZA (2) ZA200307585B (hu)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297336B2 (en) * 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
CN101111260B (zh) * 2005-02-04 2013-03-20 萨瓦克公司 存活蛋白肽疫苗
FI20055398A0 (fi) 2005-07-08 2005-07-08 Suomen Punainen Risti Veripalv Menetelmä solupopulaatioiden evaluoimiseksi
EP2594591B1 (en) * 2005-08-11 2018-06-06 Arpi Matossian-Rogers Tcr-v-beta related peptides for treatment and diagnosis of autoimmune disease
JP5415071B2 (ja) * 2005-08-19 2014-02-12 ワイス・エルエルシー Ｇｄｆ−８に対するアンタゴニスト抗体ならびにａｌｓおよびその他のｇｄｆ−８関連障害の処置における使用
ITFI20060163A1 (it) * 2006-06-29 2006-09-28 Menarini Internat Operations Luxembourg Sa Composizione farmaceutica contenente un anticorpo monoclonale anti idiotipico anti-ca-125 ed alluminio
TWI434855B (zh) 2006-11-21 2014-04-21 Hoffmann La Roche 結合物及其在免疫分析中作為參考標準之用途
WO2009104649A1 (ja) * 2008-02-22 2009-08-27 片山化学工業株式会社 合成糖脂質含有リポソーム
EP2166085A1 (en) 2008-07-16 2010-03-24 Suomen Punainen Risti Veripalvelu Divalent modified cells
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
NZ594985A (en) * 2009-03-10 2013-07-26 Biogen Idec Inc Anti-bcma (b-cell maturation antigen, cd269, tnfrsf17) antibodies
SG174992A1 (en) 2009-04-01 2011-11-28 Genentech Inc Anti-fcrh5 antibodies and immunoconjugates and methods of use
CU23736A1 (es) * 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
WO2011026242A1 (en) * 2009-09-03 2011-03-10 Vancouver Biotech Ltd. Monoclonal antibodies against gonadotropin-releasing hormone receptor
WO2012096994A2 (en) * 2011-01-10 2012-07-19 Emory University Antibodies directed against influenza
CU24070B1 (es) * 2011-12-27 2015-01-29 Ct De Inmunología Molecular Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
EP2641916A1 (en) * 2012-03-23 2013-09-25 Centre National de la Recherche Scientifique (C.N.R.S) Novel antibodies anti-sPLA2-IIA and uses thereof
MY177331A (en) 2012-06-15 2020-09-12 Pfizer Improved antagonist antibodies against gdf-8 and uses therefor
AR096687A1 (es) 2013-06-24 2016-01-27 Genentech Inc Anticuerpos anti-fcrh5
UA120753C2 (uk) 2013-12-17 2020-02-10 Дженентек, Інк. Біспецифічне антитіло до сd3 та cd20
JP2017512759A (ja) * 2014-04-10 2017-05-25 オービーアイ ファーマ インコーポレイテッド 抗体、前記抗体を産生するハイブリドーマ、前記抗体を含む薬学的組成物及びその用途
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
CA2986928A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Humanized and affinity matured antibodies to fcrh5 and methods of use
WO2018017864A2 (en) * 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Pvrig-binding agents and uses thereof
CA3044664C (en) 2016-11-30 2022-11-22 Oncomed Pharmaceuticals, Inc. Methods for treatment of cancer comprising tigit-binding agents
CU20170173A7 (es) * 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2754206B2 (ja) * 1987-11-17 1998-05-20 メクト株式会社 α２→３結合を認識するモノクローナル抗体
US6051225A (en) * 1988-10-19 2000-04-18 The Dow Chemical Company Family of high affinity, modified antibodies for cancer treatment
EP0586002B1 (en) * 1992-08-18 2000-01-19 CENTRO de IMMUNOLOGIA MOLECULAR Monoclonal antibodies recognizing the epidermal growth factor receptor, cells and methods for their production and compositions containing them
JPH07101999A (ja) * 1993-10-06 1995-04-18 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体に対する抗イデイオタイプ抗体のアミノ酸配列およびそれをコードするｄｎａ塩基配列
US6063379A (en) * 1993-12-09 2000-05-16 Centro De Inmunologia Molecular Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies
CU22702A1 (es) * 1997-10-21 2001-07-31 Centro Inmunologia Molecular Anticuerpos monoclonales anti - idiotipo, su uso en la inmunoterapia activa de tumores malignos, hibridoma que los produce y composiciones que los contienen
EP0657471B1 (en) * 1993-12-09 2001-10-24 Centro de Inmunologia Molecular Anti ganglioside monoclonal antibodies and their use in the specific active immunotherapy of malignant tumours
CU22420A1 (es) * 1993-12-29 1996-01-31 Centro Inmunologia Molecular Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
US6149921A (en) * 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CU22731A1 (es) * 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies

Also Published As

Publication number Publication date
CA2441845C (en) 2011-06-07
NO20034436L (no) 2003-12-02
EA006936B1 (ru) 2006-06-30
ATE406386T1 (de) 2008-09-15
SK12262003A3 (sk) 2004-08-03
UA76745C2 (uk) 2006-09-15
BR0208676A (pt) 2008-04-08
CU23007A1 (es) 2004-12-17
WO2002081496A3 (es) 2004-02-19
KR100863509B1 (ko) 2008-10-15
NO331533B1 (no) 2012-01-23
DE60223547T2 (de) 2008-09-18
CZ20032668A3 (cs) 2004-07-14
KR20030092048A (ko) 2003-12-03
BG108227A (bg) 2005-04-30
SK12162003A3 (sk) 2004-05-04
NO20034437D0 (no) 2003-10-03
UY27242A1 (es) 2002-07-31
NZ528598A (en) 2005-03-24
CN101054417A (zh) 2007-10-17
MY157372A (en) 2016-06-15
SI1384726T1 (sl) 2009-04-30
KR20080080680A (ko) 2008-09-04
DK1411064T3 (da) 2008-03-25
CA2441845A1 (en) 2002-10-17
CN1535282A (zh) 2004-10-06
AU2002308347B2 (en) 2006-09-14
MY137078A (en) 2008-12-31
EP1798243A2 (en) 2007-06-20
BRPI0208675B1 (pt) 2018-03-13
KR100919617B1 (ko) 2009-09-29
CN1319991C (zh) 2007-06-06
DE60223547D1 (de) 2007-12-27
EA200301097A1 (ru) 2004-02-26
NO20034436D0 (no) 2003-10-03
PL208109B1 (pl) 2011-03-31
CZ20032641A3 (cs) 2004-07-14
HK1070080A1 (en) 2005-06-10
NZ528599A (en) 2005-03-24
US20050069535A1 (en) 2005-03-31
SK287783B6 (sk) 2011-09-05
JP2004528033A (ja) 2004-09-16
IL158246A (en) 2010-05-31
IS2701B (is) 2010-11-15
IL158246A0 (en) 2004-05-12
EA006310B1 (ru) 2005-10-27
ATE477279T1 (de) 2010-08-15
HUP0401695A3 (en) 2012-05-29
IS6964A (is) 2003-09-23
EA200301098A1 (ru) 2004-04-29
JP4366080B2 (ja) 2009-11-18
AU2007231687B2 (en) 2010-09-30
CZ304424B6 (cs) 2014-04-30
EP1411064A2 (en) 2004-04-21
BR0208676B1 (pt) 2017-11-14
EP1411064B1 (en) 2007-11-14
NO20034437L (no) 2003-12-02
CN101054417B (zh) 2012-07-11
AR033122A1 (es) 2003-12-03
ECSP034787A (es) 2004-01-28
PT1411064E (pt) 2008-02-12
WO2002081496A2 (es) 2002-10-17
AR033123A1 (es) 2003-12-03
AU2007231687A1 (en) 2007-11-22
DE60228561D1 (de) 2008-10-09
IS6965A (is) 2003-09-23
MXPA03008739A (es) 2003-12-11
UY27243A1 (es) 2002-09-30
MXPA03008738A (es) 2003-12-11
EP1798243A3 (en) 2007-10-17
CN100349920C (zh) 2007-11-21
EP1798243B1 (en) 2010-08-11
HRP20030806B1 (en) 2011-11-30
BG108228A (bg) 2005-04-30
PL371770A1 (en) 2005-06-27
BG66293B1 (en) 2013-02-28
CA2443372C (en) 2013-05-28
MY145703A (en) 2012-03-30
CZ296276B6 (cs) 2006-02-15
US20100297008A1 (en) 2010-11-25
PT1384726E (pt) 2008-12-05
US20040253233A1 (en) 2004-12-16
ZA200307585B (en) 2004-09-16
SG161737A1 (en) 2010-06-29
SI1411064T1 (sl) 2008-04-30
HK1066818A1 (hu) 2005-04-01
WO2002081661A3 (es) 2003-01-03
UA75393C2 (en) 2006-04-17
HUP0401695A2 (en) 2006-08-28
JP2004525953A (ja) 2004-08-26
HK1109160A1 (en) 2008-05-30
HU228106B1 (en) 2012-11-28
HRP20030805B1 (en) 2011-11-30
ZA200307679B (en) 2005-03-30
KR100946168B1 (ko) 2010-03-11
HUP0401355A3 (en) 2012-05-29
EP1384726A2 (en) 2004-01-28
US8758753B2 (en) 2014-06-24
HU228105B1 (en) 2012-11-28
ES2312610T3 (es) 2009-03-01
EP1384726B1 (en) 2008-08-27
ES2296986T3 (es) 2008-05-01
AU2002308348B2 (en) 2007-11-22
HRP20030806A2 (en) 2005-08-31
HRP20030805A2 (en) 2005-08-31
ATE378356T1 (de) 2007-11-15
BR0208675A (pt) 2004-08-03
PL371937A1 (en) 2005-07-11
SK287914B6 (sk) 2012-03-02
BG66304B1 (bg) 2013-03-29
UA86768C2 (ru) 2009-05-25
CN1507452A (zh) 2004-06-23
PE20020972A1 (es) 2003-01-02
DK1384726T3 (da) 2008-12-15
KR20030087053A (ko) 2003-11-12
WO2002081661A2 (es) 2002-10-17
CA2443372A1 (en) 2002-10-17
ECSP034788A (es) 2004-01-28

Similar Documents

Publication Publication Date Title
HUP0401355A2 (hu) Kombinált immunterápiás készítmények gangliozidokat túlexpresszáló tumorok kezelésére
NO20013906D0 (no) Fremgangsmater for behandling av tumorer og metastaser ved a bruke en kombinasjon av antiangiogeniske- og immunoterapier
Raez et al. Lung cancer immunotherapy
DK0586002T3 (da) Monoklonale antistoffer, som genkender epidermisvækstfaktor-receptoren, celler og fremgangsmåder heraf og præparater indeho
AU2190997A (en) Humanized anti-cd40 monoclonal antibodies and fragments capable of blocking b cell activation
WO2001095919A3 (en) A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
WO1998016238A3 (en) Cancer immunotherapy using tumor cells combined with mixed lymphocytes
NZ210867A (en) Tumour-specific monoclonal antibodies, production thereof and use
DE69332643T2 (de) Menschliche, neutralisierende, monoklonale antikörper gegen das respiratorische synzytialvirus
AU7856700A (en) Composition and method of cancer antigen immunotherapy
CA2360382A1 (en) Use of antibodies for the vaccination against cancer
WO2004022590A3 (en) Immunogenic muc1 glycopeptides
DK0522078T3 (da) GP75 som en tumorvaccine mod melanom
MY138833A (en) Immunotherapeutic combination for the treatment of tumors that over-express receptors with tyrosine kinase activity
CA2440610A1 (en) Induction of tumor immunity by variants of folate binding protein
TR200704213T2 (tr) İnterleukin-2'nin reseptörüne bağlanmasını önleyebilen otoantikorlar üretmek için immünoterapötik formülasyonlar, bunların kanser tedavisinde kullanımı.
US20050169929A1 (en) Use of a vaccine for active immunization against cancer
MXPA04000652A (es) Identificacion de antigenos especificos del tumor por medio de seleccion de bibliotecas de acido desoxirribonucleico complementario con sueros y uso de antigenos en tratamiento de tumores.
Fagerberg The idiotypic network response in cancer patients treated with monoclonal antibodies.
Ferrone et al. Active Specific Immunotherapy of Malignant Melanoma with Anti‐idiotypic Monoclonal Antibodies
JH et al. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees